Glenmark out-licences pain molecule to Sanofi

04 May 2010 Evaluate

Drug-maker Glenmark has formalised an outlicensing deal with Sanofi-aventis to further develop and commercialise the former's novel agents to treat chronic pain, including prospective pain molecule GRC 15300.

 

The deal breaks a drought of close to two-and-a-half years on the outlicensing front, besides marking a turnaround on the research front for the company. Glenmark will receive an upfront payment of $ 20 million from the Sanofi deal, with milestone and 'double-digit' royalty payments as the molecule is further developed and hits the market. The total value of these payments is pegged at $325 million.

 

The deal outlines exclusive marketing rights for Sanofi in North America, European Union and Japan, subject to Glenmark's right to co-promote the products in the US and five Eastern European countries. Sanofi-Aventis will also have co-marketing rights in 10 other countries including Brazil, Russia, and China, while Glenmark will retain exclusive rights in India and other countries of the rest of the world.

crackcrack

Glenmark Pharma Share Price

1358.90 -62.95 (-4.43%)
25-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.85
Dr. Reddys Lab 1173.55
Cipla 1525.50
Lupin 2018.35
Zydus Lifesciences 859.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...